Optimum Infinite (tisilfocon A) Orthokeratology Lenses II
Contamac, Ltd. · Decision date Feb 10, 2026
What did the FDA approve?
FDA records P240045 as an original PMA application. The recorded decision is approval, dated Feb 10, 2026.
FDA approval order statement
Approval for Optimum Infinite (tisilfocon A) Ortho-k Lenses, Optimum Infinite (tisilfocon A) Orthokeratology Lenses II.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Ophthalmic
- Decision date
- Feb 10, 2026
Regulatory record facts
- Identifier
- P240045
- Regulatory pathway
- Premarket approval application
- Applicant
- Contamac, Ltd.
- Product code
- NUU
- Decision code
- APPR
- Decision date
- Feb 10, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Lens, contact, orthokeratology, overnight.
- Applicant
- Contamac, Ltd.
- Product code
- NUU
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P240045 received
Application receipt date recorded by FDA.
P240045 · FDA decision
APPR
Timeline entries are records held by MedtechLedger for P240045. View FDA’s full supplement list.
Related devices and submissions
Explore the linked device profile
Other records with product code NUU
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Tianjin MasterVision Technology Co., Ltd. | PMA approval | Aug 5, 2026 | FDA | |
| Euclid Vision Corporation | PMA supplement | Apr 2, 2026 | FDA | |
| Euclid Vision Corporation | PMA supplement | Mar 12, 2026 | FDA | |
| Euclid Vision Corporation | PMA supplement | Mar 6, 2026 | FDA | |
Boston Orthokeratology (oprifocon A)P010062/S015 | Bausch & Lomb | PMA supplement | Dec 16, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Contamac, Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Carlton House, Shire Hill, Saffron Walden, CB11 3AU
Sources and methodology
- Original FDA record: P240045
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


